Day: April 28, 2025

ROCKVILLE, Md. and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that it has presented results from five preclinical studies during poster presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois, USA. These poster presentations feature five of the company’s drug candidates: novel tyrosine kinase inhibitor (TKI) olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 TKI APG-2449, embryonic ectoderm development (EED) inhibitor APG-5918, and IAP antagonist AS03157. Dr. Yifan Zhai,...

– NDA submitted for the treatment of central diabetes insipidus –– Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch – DEER PARK, Ill., April 28, 2025 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ET-600, Eton’s proprietary, patented oral solution of desmopressin under development for the treatment of central diabetes insipidus. The Company expects the application to be assigned a 10-month FDA review, allowing for potential approval and launch in the first quarter of 2026. “The NDA submission for ET-600 is another...

– ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors – – Findings support continued evaluation of ARV-393 combinations in non-Hodgkin lymphoma – NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today presented data from preclinical combination studies of ARV-393, the company’s investigational PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 protein (BCL6) degrader. BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. Data demonstrated synergistic antitumor activity, including complete...

TDC NET A/S – Publication of Prospectus Supplement NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES. NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO ANY PERSON IN ANY JURISDICTION WHERE RELEASE, PUBLICATION OR DISTRIBUTION TO SUCH PERSON IS RESTRICTED BY ANY LAW OR REGULATION APPLICABLE IN SUCH JURISDICTION. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR ISSUE OR INVITATION TO PURCHASE OR SUBSCRIBE FOR, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES. Copenhagen, 28 April 2025: TDC NET A/S (TDC NET) today announces that the Supplement dated 28 April 2025 (the “Prospectus Supplement”) to the Base Prospectus dated 22 April 2025 relating to TDC NET’s EUR 3,500,000,000 Euro Medium Term Note (EMTN) programme has been approved by...

OMA SAVINGS BANK PLC, INVESTOR NEWS 28.4.2025 Oma Savings Bank Plc to publish its January-March 2025 interim report on 5 May 2025 Oma Savings Bank Plc will publish its interim report for January-March 2025 on 5 May 2025. The announcement will be available on the company’s website after publication at https://www.omasp.fi/en/investors OmaSp will hold a Finnish-language webcast on 5 May 2025 at 11.00 EET, and the link to the webcast can be accessed from here. The results will be presented by CEO Karri Alameri. The webcast will be recorded, and the recording will be available later the same day at https://www.omasp.fi/en/investors Please join us for the results announcement webcast. Oma Savings Bank Plc Additional information: Karri Alameri, CEO, tel. +358 45 656 5250, karri.alameri@omasp.fiSarianna Liiri, CFO, tel. +358 40 835 6712, sarianna.liiri@omasp.fi DISTRIBUTION: Nasdaq...

LONGUEUIL, Québec, April 28, 2025 (GLOBE NEWSWIRE) — Azimut Exploration Inc. (“Azimut” or the “Company”) (TSXV: AZM) (OTCQX: AZMTF) is pleased to announce that it has entered into a subscription agreement with Centerra Gold Inc. (“Centerra”) (TSX: CG) (NYSE: CGAU) for a non-brokered private placement of 9,430,000 common shares of the Company at a price of $0.60 per share for gross proceeds of $5,658,000 (the “Offering”). Centerra will become a strategic investor in the Company, acquiring approximately 9.9% of the issued and outstanding common shares following completion of the Offering. Centerra’s investment supports Azimut’s strategy to create value through greenfield discoveries in Québec, Canada. The Company has demonstrated its ability to generate and advance quality targets for precious metals and critical minerals. Following...

Signature of the Rafale Marine contract for India Saint-Cloud, France, April 28, 2025 – The Inter-Governmental Agreement between India and France has been signed today allowing the signature, in the presence of the Chairman and CEO of Dassault Aviation, Éric Trappier, of the contract for India’s acquisition of 26 Rafale Marine to equip the Indian Navy. This contract follows the announcement in July 2023 of the selection of the Rafale Marine, for which the Indian Navy will be the first user outside France, after an international consultation. It confirms the Indian authorities’ satisfaction with the aircraft’s capabilities and their desire to broaden the spectrum of its operational use. This new acquisition testifies to the importance of the strategic relationship between India and France and the recognition of the Rafale...

The Supervisory Board of Nordic Fibreboard AS approved on28th of April 2025 the audited annual report for the year 2024. The supervisory board decided to present the annual report and profit allocation proposal as prepared by the management for the approval of the general meeting of shareholders. Overview of operating results Revenue and operating results Consolidated net sales for 2024 were € 7.59 million, which is a decrease of 1.5% compared to 2023 sales of € 7.71 million. The sales revenue from the production of fibreboard was € 7.57 million in 2024 (2023: € 7.66 million). Sales revenue in 2024 remained at the same level compared to 2023. Changes occurred in market shares, as the 2023 sales revenue included 17% sales to a major Danish customer, with whom cooperation ended in June 2023. The loss of this volume has been successfully...